Flaxseed Improves Glucose and Lipid Metabolism in Mexican Subjects with Type 2 Diabetes: A Parallel Randomized Clinical Trial.

Abstract

Introduction: Type 2 diabetes is a significant health concern in the 21st century, and its prevalence continues to rise despite efforts to promote preventive lifestyle changes. This increase has led to higher economic burdens, prompting the search for non-pharmacological methods to manage glucose levels.

Objective: To assess the effects of flaxseed consumption on biochemical markers (glucose, glycated hemoglobin, total cholesterol, and triglycerides) in adult patients with Type 2 diabetes in Oaxaca, Mexico.

Materials and methods: Participants were recruited and randomized into clinical trials between April and June 2023, and the study protocol was approved by a Human Research Ethics Committee.

Results: Consuming 16 g of flaxseed daily for three months led to a significant decrease in glucose, total cholesterol, and triglyceride levels (p < 0.001) in Type 2 diabetes patients in the intervention group (n = 82). Belonging to the control group (n = 84) was correlated with presenting higher levels of glycated hemoglobin (Spearman's Rho 0.640; p < 0.001), higher levels of glucose (Spearman's Rho 0.352; p < 0.001), total cholesterol (Spearman's Rho 0.796; p < 0.001), and triglycerides (Spearman's Rho 0.700; p < 0.001).

Conclusions: A daily intake of 16 g of flaxseed is an effective supplementary treatment for adult Mexican patients with Type 2 diabetes, as evidenced by reduced levels of glycated hemoglobin, glucose, cholesterol, and triglycerides in the intervention group. Potential implications for clinical practice: Healthcare providers may consider recommending flaxseed in the diets of patients with obesity, prediabetes, or Type 2 diabetes to improve glucose and lipid metabolism and overall metabolic health.